New Cancer Hope: Whitehawk Targets SEZ6 Protein

Whitehawk Therapeutics has revealed that SEZ6, a protein, is a promising target for new cancer treatments, particularly for small cell lung cancer (SCLC) and other neuroendocrine tumors. Their upcoming drug, HWK-206, which targets SEZ6, could be a game-changer, with clinical trials set to begin in late 2026. The findings were shared at a major oncology conference, highlighting SEZ6's potential in combination with other therapies. What does it mean for you? If you or someone you know is affected by SCLC or similar cancers, this research offers hope for more effective treatment options on the horizon. Keep an eye on developments from Whitehawk Therapeutics as they move closer to clinical trials.